Turbine AI
Simulation-driven drug discovery company delivering population targeted cancer therapies.
- B2B
- manufacturing
- commission
- health
- pharmaceutical
- biotechnology
- deep tech
- machine learning
- artificial intelligence
- hardware
- dt and ls
- biotechnology
- horizon europe
- spinout
- core ai
- ai applications
- oncology
- eit ecosystem
- genetics and genomics
- neurology
- drug development
- eit health
- nif defense security and resilience
- ai drug discovery
- tech for biotech and pharma
- techbio
- digital pharma
- techbio drug discovery
- biomarkers
- niÜ
- nif health crisis preparedness
- compbio
- nif biotech
- rna
- gold track (eit health)
- gold track 2020 (eit health)
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor investor investor investor | €0.0 | round |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor | €0.0 | round | |
| investor | €0.0 Valuation: €0.0 19.8x EV/Revenue | round | |
* | N/A | Late VC | |
| Total Funding | 000k | ||
| HUF | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 8 % | 51 % | 47 % | 43 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | 1 % | 1 % | 6 % | 3 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Turbine AI has developed a cell simulation platform that uses machine learning to model human biology and predict the effectiveness of cancer treatments. This technology, called Simulated Cells™, aims to improve the drug discovery and development process by identifying promising therapeutic targets and patient populations that are most likely to respond to treatment.
The company collaborates with pharmaceutical companies, such as AstraZeneca, to apply its simulation platform to specific challenges in oncology, like understanding drug resistance in hematological cancers. By simulating how cancer cells behave at a molecular level, Turbine AI can provide insights that are difficult to obtain through traditional laboratory experiments alone.
The platform is designed to de-risk drug development, potentially reducing the time and cost associated with bringing new therapies to market. The company offers a "Virtual Lab" for potential clients to explore the technology's capabilities.
Keywords: cell simulation, oncology, drug discovery, machine learning, personalized medicine, cancer treatment, R&D, biotechnology, pharmaceutical, hematology